Clovis Oncology products
R
-
Rubraca® — rucaparib
-
Indication: a PARP inhibitor approved for:
-
Treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer in adults with deleterious or suspected deleterious BRCA mutations after ≥2 lines of chemotherapy
-
Maintenance therapy in platinum-sensitive ovarian cancer (independent of biomarker status)
-
-
Status: Clovis’s only marketed drug; sold in 2023 during their bankruptcy proceedings
-
Pipeline / Investigational
-
Lucitanib
-
A VEGFR/FGFR inhibitor under investigation for advanced solid tumors
-
-
177-Lu FAP‑2286
-
A peptide-targeted radionuclide therapy (PTRT) in early clinical trials, targeting fibroblast activation protein (FAP) for oncology imaging and treatment
No comments:
Post a Comment